Core Insights - Dalirelix, developed by Xiansheng Pharmaceutical in collaboration with Swiss Idorsia, was approved by the National Medical Products Administration in June 2023 for treating adult insomnia characterized by difficulty in falling asleep and/or maintaining sleep [1][2] - The drug has shown excellent performance in improving sleep onset time, nighttime awakening, self-reported sleep duration, sleep quality, and daytime functioning, with good safety and tolerability [1] - The prevalence of sleep disturbances among individuals aged 18 and above in China is reported at 48.5%, with symptoms including difficulty falling asleep, frequent awakenings, and early morning awakenings [1] Company Initiatives - Xiansheng Pharmaceutical plans to invest 10 million yuan annually, totaling 30 million yuan over three years, to further research the value of Dalirelix for patients [2][4] - The research will include subgroup studies on the efficacy and safety of Dalirelix for patients with insomnia combined with anxiety/depression, cancer, cardiovascular diseases, autoimmune diseases, obstructive sleep apnea, and stroke [2] - The "All Heavy Search Plan" aims to expand research in the field of neurology and insomnia, providing more real-world medication evidence for patients with comorbid neurological and psychiatric conditions [4]
先声药业：未来三年拟投入3000万元 用于睡眠药物的进一步研究